3.5 Publications

May 20, 2021

Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing

Nature Genetics in Medicine, Tempus-authored — 2021 Update: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG) View the full publication here. Authors: David T. Miller, Kristy Lee, Adam S. Gordon, Laura M. Amendola, Kathy Adelman, Sherri J. Bale, Wendy K. Chung, Michael H. Gollob, Stev...

May 20, 2021

Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First-line Use

ASCO Annual Meeting 2021, Tempus-authored — Background: A growing number of genomic alterations inform treatment of advanced/metastatic colorectal cancer (mCRC). However, use of comprehensive genomic profiling (CGP) is limited in the first-line (1L) setting. Based on the Tempus xT next-generation sequencing assay, we estimated the impact of expanded ...

May 20, 2021

Primary Pancreatic Adenocarcinoma (PPDA) and Metastatic Pancreatic Adenocarcinoma (MPDA): Are They Genomically Distinct?

ASCO Annual Meeting 2021, Tempus-authored — Background: PDA is an aggressive disease with a dismal prognosis. Advances in next-generation sequencing (NGS) have enabled targeted therapies, revolutionizing treatments of several solid tumors. Their role in the management of PDA is limited, in part due to the paucity in our understand...

May 20, 2021

Expanding the Molecular Taxonomy of NUT Midline Carcinomas With Multiomic Analyses

ASCO Annual Meeting 2021, Tempus-authored — Background: NUT midline carcinoma (NMC) is an aggressive squamous cell carcinoma molecularly defined by a chromosomal rearrangement of nuclear protein in testis (NUTM1) with bromodomain-containing protein 3 or 4 (BRD3/4). While NMCs are characterized by this rare canonical gene rearrangement little is known about the transc...

May 20, 2021

Leveraging Machine Learning Technology to Efficiently Identify and Match Patients for Precision Oncology Clinical Trials

ASCO Annual Meeting 2021, Tempus-authored — Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site netwo...

May 20, 2021

Comprehensive Genomic and Transcriptomic Profiling of Pediatric Malignancies Using the Tempus xT Next-Generation Sequencing Assay to Identify Clinically Meaningful Alterations

ASCO Annual Meeting 2021, Tempus-authored — Background: Our understanding of the genomic makeup of childhood cancers has accelerated over the past decade largely due to next-generation sequencing (NGS) utilized to identify genetic drivers, aid diagnostics and risk stratification, and detect therapeutic targets. Here, we present the genomic and transcript...

May 20, 2021

Multimodal Profiling of Biliary Tract Cancers to Detect Potentially Actionable Biomarkers and Differences in Immune Signatures Between Subtypes

ASCO Annual Meeting 2021, Tempus-authored — Background: Biliary tract cancers (BTC) are increasingly subtyped by molecular alterations, but little is known about the relationship between gain-of-function mutations and the RNA transcript expression of immune-related pathways. Methods: A sample of retrospective, clinicogenomic and transcriptomic data from de-identified records of patients...

May 20, 2021

A Review of Evidence Supporting NCCN Category 2B Off-label Recommendations for Determination of Medicare Reimbursement Eligibility

ASCO Annual Meeting 2021, Tempus-authored — Background: Antineoplastic indications supported by a category 1 or 2A NCCN recommendation are reimbursed by insurance and Medicare, as are FDA-approved indications. While initial reimbursement requests for “off-label” NCCN category 2B indications may be denied, Medicare will reimburse off-label antineoplastic use supported by evidence f...

May 20, 2021

Rate of Incidental Germline Findings Detected by Tumor-Normal Matched Sequencing in Cancer Types Lacking Hereditary Cancer Testing Guidelines

ASCO Annual Meeting 2021, Tempus-authored — Background: Up to 10% of all cancers are associated with hereditary cancer syndromes; however, guidelines for germline testing are currently limited to patients and families with specific cancer types (ovarian, breast, prostate, pancreatic, etc.). Although germline alterations have been shown in genes associated with cance...

May 20, 2021

The TIME Trial Network to Facilitate Rapid Clinical Trial Activation, Patient Screening, and Enrollment in Molecularly Targeted Trials

ASCO Annual Meeting 2021, Tempus-authored — Background: Clinical trials that require patients to have specific actionable mutations based on next generation sequencing (NGS) present unique problems, such as recruiting patients with rare mutations, low enrollment rates, and distance between patients and trial sites. Such barriers can slow the pace of tr...

Show More